Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Home About Us My Account Personal Library Customer Service    
Welcome Guest
(login/register)
US: 800.298.5699
Int'l: +1.240.747.3093
Quick Search
Advanced Search >
Research Assistance
Send us a request >
Latest Research by Email
Receive email alerts of new market research reports in your industry.
Sign Up Today >
Home > Back to Publisher > Report Information Email a colleague | Printer format

Commercial Insight: Antithrombotics - Pipeline products to dampen the impact of patent expiries and cost containment initiatives

Datamonitor
December 19, 2006
290 Pages - Pub ID: DFMN1424664
 
Questions about this report >
Order by fax >
XE.com
Abstract

Table of
Contents
Related Reports


Countries covered: Global

Introduction

The ageing of the population will result in an increased incidence of coronary artery disease, heart failure and stroke. In addition to these epidemiological forces, the antithrombotics market will be sustained by the forthcoming launch of innovative novel agents whose sales revenue is expected to dampen the commercial impact of generic incursion in blockbuster proceeds.

Scope
  • Country specific event-driven sales forecasts for the period 2006-15 for the US, Japan, France, Germany, Italy, Spain and the UK
  • Discussion of recent trials and market-shaping future key events
  • Profiles of the country and market specific issues which will impact future sales in the market including generic erosion and class switching
  • Case studies evaluating the commercial impact of two developmental agents with blockbuster potential
Highlights

Demographic trends lead to an increase in the patient population requiring antithrombotic therapy. However, the rising age of the population across all developed regions is increasing the fiscal burden on healthcare payors which are likely to respond by limiting the reimbursement potential of therapies and put pricing pressure on all agents.

The highest selling brands in the antidiabetics market are Lovenox (enoxaparin) and Plavix (clopidogrel), but these agents are subject to forthcoming genericization and will thus not contribute to the growth of the antithrombotics market in the medium-to-long term. Pipeline agents are expected to become significant drivers in the market.

The antithrombotics market is characterized by pockets of high unmet need and a broad spectrum of similarly efficacious therapeutic strategies. There is regional bias in the choice and popularity of therapeutic strategies driven by cultural reasons as well as infrastructural confines.

Reasons to Purchase
  • Quantify future size and scope of the antithrombotics market and potential for new products
  • Analyze options to expand commercial potential through pursuit of new indications
  • Formulate successful launch strategies in a highly competitive mature market
Please note, this file is delivered as a Zip file.

Related Reports:
Mapping the Healthcare Landscape Bringing pharmaceuticals into focus
Worldwide Biotech - November 2009
Cardiovascular Outlook: Pharmaceutical, Medical Device, New Technologies - Past, Present, and Future
Eye Care in Denmark
The Pharmaceutical Market: UK
The Pharmaceutical Market: Ukraine
Cardiovascular and Circulatory System Acute Coronary Syndromes Therapy Area Pipeline Report
Cardiovascular and Circulatory System Angina Therapy Area Pipeline Report
Cardiovascular and Circulatory System Atherosclerosis or Coronary Artery Disease Therapy Area Pipeline Report
Cardiovascular and Circulatory System Atrial Fibrillation Therapy Area Pipeline Report

Privacy Policy    |    Terms and Conditions    |    Site Map    |    Return Policy    |    Press    |    Help FAQs
Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/24/2009 - 2